

Figure 1. The flow of clusters (ICUs) and participants (patients) through the trial.




Table 1. Baseline ICU and Patient-Level Characteristics

Characteristics	Feeding guideline 48 ICUs, 1399 pts	Control 49 ICU, 1373 pts	P-value
ICU-level characteristics			
Tertiary, No. (%)	34 (70.8)	37 (75.5)	0.61
ICU type, No. (%)			0.97
Emergency	2 (4.2)	2 (4.1)	
Medical	1 (2.1)	1 (2)	
Neuro	1 (2.1)	1 (2)	
Surgical	2 (4.2)	2 (4.1)	
General	42 (87.5)	43 (87.8)	
Geographical region, No. (%)			0.623
Western	8 (16.7)	10 (20.4)	
Eastern	25 (52.1)	25 (51)	
Central Region	12 (25)	12 (24.5)	
Northeast	3 (6.2)	2 (4.1)	
Patient-level characteristics			
Age, mean \pm SD, y	61.0 \pm 17.6	60.1 \pm 17.7	0.98
Male, No. (%)	938(67.0%)	928(67.6%)	0.56
Weight, mean \pm SD, kg	63.6 \pm 11.1	65.1 \pm 11.2	0.16
BMI, mean \pm SD, kg/m ²	22.8 \pm 3.2	23.1 \pm 3.2	0.27
APACHE II score, mean \pm SD	18.3 \pm 6.8	18.6 \pm 7.6	0.63
NUTRIC score, mean \pm SD	4.7 \pm 2.2	4.7 \pm 2.3	0.80
SOFA score, mean \pm SD	7.5 \pm 3.4	8.1 \pm 3.7	0.07
SOFA score for individual organ systems, mean\pmSD			
Respiration	2.2 \pm 1.2	2.3 \pm 1.1	0.15
Renal	0.8 \pm 1.3	0.9 \pm 1.4	0.29
Cardiovascular	1.1 \pm 1.7	1.4 \pm 1.7	0.31
Gastrointestinal function, No. (%)			0.09
AGI-I	1019 (75.9%)	888 (66.5%)	
AGI-II	236 (17.6%)	290 (21.7%)	
AGI-III	50 (3.7%)	126 (9.4%)	
AGI-IV	37 (2.8%)	31 (2.3%)	

ICU denotes intensive care unit; BMI denotes body mass index; APACHE, acute physiology and chronic health evaluation; NUTRIC denotes nutrition risk in the

critically ill; SOFA denotes sequential organ failure assessment; AGI denotes acute gastrointestinal injury.

Table 2. Process measures of nutritional therapy

Process Measures	Feeding guideline 48 ICUs, 1399 pts	Controls 49 ICU, 1373 pts	Difference(95% CI)	P
Mean time to start EN, d, mean±SD	1.20 ±1.42	1.55 ±1.64	-0.40 [-0.71, -0.09]	0.01
Mean time to start PN, d, mean±SD	1.29 ±1.74	0.80 ±1.40	1.06 [0.44, 1.67]	0.001
Mean nutrition support days within first seven days after enrollment /10 patient-days, mean±SD				
EN and/or PN	8.29 ±2.26	8.34 ±2.43	0.10 [-0.44, 0.65]	0.71
EN	7.51 ±2.82	6.49 ±3.42	1.09 [0.46, 1.73]	0.001
PN	1.66 ±3.12	3.72 ±4.18	-1.68 [-2.86, -0.49]	0.006
Mean energy delivered for patients within first seven days after enrollment / fed patient* -days, kcal mean±SD				
EN	1070.8 ±500.6	1015.9 ±423.5	64.45 [-49.13,178.04]	0.26
PN	776.5 ±472.9	829.9 ±611.1	-43.21 [-245.8,159.41]	0.67
Patients never fed during first seven days, No. (%)	7(0.6%)	12(0.9%)	0.2% [-0.6%; 1.0%]	0.67
Patients received EN during first two days after enrollment, No. (%)	883(65.8%)	687(51.4%)	16.5% [7.0%; 25.9%]	<0.001
Patients received PN during first two days after enrollment, No. (%)	250(18.6%)	555(41.5%)	-19.5% [-33.1%; -5.9%]	0.005
Patients fed during first two days after enrollment, No. (%)	1036(77.2%)	1042(78.0%)	0.7% [-8.4%; 9.9%]	0.87
Patients received EN or PN first two days after enrollment, No. (%)	1022(76.2%)	1006(75.3%)	3.2 % [-6.0%; 12.5%]	0.49
EN tolerance score after enrollment, mean±SD				

Day 1	0.2 ±0.8	0.2 ±0.8	-0.03 [-0.23, 0.16]	0.74
Day 2	0.3 ±0.9	0.3 ±1.0	-0.05 [-0.24, 0.14]	0.62
Day 3	0.4 ±1.0	0.4 ±1.0	-0.02 [-0.20, 0.16]	0.85
Day 4	0.3 ±0.9	0.4 ±1.1	-0.06 [-0.23, 0.11]	0.47
Day 5	0.3 ±0.9	0.4 ±1.1	-0.11 [-0.25, 0.04]	0.16
Day 6	0.3 ±0.9	0.4 ±1.0	-0.08 [-0.23, 0.07]	0.30
Day 7	0.3 ±0.9	0.4 ±1.0	-0.10 [-0.25, 0.05]	0.18
Days requiring prokinetic agents within first seven days enrollment /10 patient-days, mean±SD	1.1 ±2.7	1.0 ±2.5	0.37 [-0.29, 1.03]	0.26
Proportion of patients who received a post-pyloric feeding tube (patients receiving EN) within first seven days after enrollment, No. (%)	91(6.5%)	149(10.9%)	-3.1% [-9.3%; 3.1%]	0.32

EN denotes enteral nutrition, and PN denotes parenteral nutrition. *fed patients denotes patients who received oral intake, EN or PN, either alone or in combination

Table 3. Patient-centered outcomes and adverse events for all enrolled patients

Outcome Measure	Feeding guideline 48 ICUs, 1399 pts	Control 49 ICU, 1373 pts	Difference (95% CI)	P-value	ICC or Design Effect	
					Feeding guideline	Control
All-cause mortality at day 28, No (%)	188(14.2%)	205(15.2%)	-1.59% [-4.34%, 1.15%]	0.42	0.11	0.05
ICU-free days within 28 days, d	9.1 ±8.9	8.7 ±8.8	0.48 [-1.02, 1.98]	0.53	0.13	0.14
Incidence of new infections in ICU, No (%)	97(6.9%)	92(6.7%)	0.13% [-1.87%, 2.13%]	0.93	0.21	0.26

ICU denotes intensive care unit; CI denotes confidence interval; ICC denotes intraclass correlation coefficient.

Table 4. Organ failure-related outcomes

Outcome Measure	Feeding guideline 48 ICUs, 1399 pts	Control 49 ICU, 1373 pts	Difference (95% CI)	P-value
New-onset organ failure within first seven days after enrollment, patients/No. (%)				
New-onset respiratory failure	178(13.3%)	138(10.3%)	3.1% [-0.8%; 6.9%]	0.11
New-onset cardiovascular failure	88(6.6%)	97(7.3%)	-1.2% [-3.8%; 1.4%]	0.36
New-onset renal failure	75(5.6%)	82(6.2%)	-1.1% [-3.0%; 0.7%]	0.22
Organ support therapy within first seven days after enrollment, treatment days/10 patient-days				
Renal replacement therapy	0.97 ±2.50	1.46 ±3.05	-0.48 [-0.88, -0.08]	0.02
Vasoactive agents	2.19 ±3.39	2.98 ±3.75	-0.73 [-1.34, -0.12]	0.02
Mechanical ventilation ^a	7.18 ±3.85	7.28 ±3.80	-0.01 [-0.63, 0.61]	0.97

CI denotes confidence interval.

^a non-invasive mechanical ventilation included